Biomedical subjects

B Modrau

Publications and source records attributed to B Modrau.

4 recordsLinked to original sources

PubMed1999

Contrast-enhanced transcranial color-coded duplex sonography: efficiency and validity.

OBJECTIVE: To evaluate the diagnostic efficiency and accuracy of contrast-enhanced transcranial color-coded sonography (CE-TCCS). BACKGROUND: TCCS is hampered by insufficient ultrasonic penetration in 20% of cerebrovascular patients. METHODS: In 47 patients whose basal arteries could not be assessed adequately, 59 TCCS examinations were performed before and after administration of the ultrasonic contrast agent (CA) Levovist. The assessability of different basal cerebral arteries after CA administration was evaluated off-line. Angiographic records were available from 11 patients. RESULTS: Satisfactory investigation of the middle cerebral artery, the anterior cerebral artery, the P1 and P2 segments of the posterior cerebral artery, and the supraclinoid portion of the internal carotid artery siphon was possible in 5.1%, 28.8%, 35.6%, 55.9%, and 47.5% of patients before, and in 84.7%, 91.5%, 93.2%, 94.5%, and 93.2% of patients after contrast enhancement. Stenoses or occlusions of basal cerebral arteries were registered in 28 patients (60%). CE-TCCS diagnosis was confirmed by digital subtraction angiography or magnetic resonance angiography in 10 of the 11 patients, leading to positive and negative predictive values of 0.86 and 1.00. CONCLUSION: Contrast enhancement improves the diagnostic potential of TCCS significantly in patients with temporal bone window failure, and proved to be a reliable method for detecting middle cerebral artery and siphon occlusion.

Adult↗

PubMed1999

Sonographic monitoring of midline shift in hemispheric infarctions.

BACKGROUND AND OBJECTIVE: Transcranial color-coded sonography (TS) allows a noninvasive, accurate evaluation of lateral displacement of the third ventricle. The authors studied the prognostic value of TS monitoring of the midline shift (MLS) in acute hemispheric stroke. METHOD: Sixteen patients with acute middle cerebral artery (MCA) occlusion were investigated. On admission, the median modified Scandinavian Stroke Scale (mSSS) score was 6.0 (range, 5 to 8). Five patients died from cerebral herniation (group 1), 10 survived (group 2), and 1 patient (Patient 16) survived after decompressive surgery. TS was performed on days 1 to 4 (10 +/- 3, 32 +/- 4, 57 +/- 5, and 82 +/- 5 hours after onset of symptoms). Distance from the TS probe to the center of the third ventricle was measured both from the symptomatic (A) and asymptomatic (B) sides. MLS was calculated using the formula MLS = (A - B)/2. RESULTS: Ten hours after stroke onset, MLS and mSSS scores were not significantly different between the two groups. At 32, 57, and 82 hours, MLS was higher in group 1 (32 hours, p = 0.001; 57 hours, p = 0.003; 82 hours, p = 0.023) whereas there was no difference in mSSS score after 32 hours. All patients with an MLS < 4 mm at 32 hours survived, whereas patients with an MLS > 4 mm died as a result of cerebral herniation, with the exception of the one patient who underwent decompressive hemicraniectomy. CONCLUSIONS: The study of MLS at 32 hours after stroke onset in patients with severe MCA infarctions may identify patients who are unlikely to survive. The value of MLS in determining the indication of decompressive craniectomy merits further study.

Adult↗

PubMed1999

Safety and ultrasound-enhancing potentials of a new sulfur hexafluoride-containing agent in the cerebral circulation.

Insufficient ultrasound penetration through the temporal bone is a serious limitation of transcranial ultrasound diagnostics. In a phase I study, the authors studied safety and ultrasound enhancing potentials of the new transpulmonary ultrasound contrast agent SonoVue, which contains sulfur hexafluoride gas microbubbles stabilized by a phospholipid shell. Twelve healthy volunteers received four different doses of SonoVue (0.3 ml, 0.6 ml, 1.2 ml, and 2.4 ml) intravenously. The duration of ultrasound contrast enhancement was measured by transcranial Doppler sonography (TCD) and transcranial color-coded sonography (TCCS). Safety and tolerability was monitored during the study and for 24 hours after contrast agent administration. TCD: Duration of spectral enhancement (signal intensity of 5 dB over baseline) was observed dose-related (p < 0.0001; Friedman-test) for (0.3 ml) 136 +/- 63.4 seconds; (0.6 ml) 191 +/- 63.3 seconds; (1.2 ml) 314 +/- 88 seconds; (2.4 ml) 434 +/- 168 seconds [mean +/- SD]. Dependent on dosage, the peak signal amplification in TCD was significantly different (p < 0.001; Friedman-test) as well: (0.3 ml) 24.5 +/- 2.0 dB; (0.6 ml) 26.0 +/- 1.6 dB; (1.2 ml) 27.6 +/- 2.2 dB; (2.4 ml) 28.4 +/- 2.2 dB (mean +/- SD). TCCS: Mean time of optimal enhancement increased from 214 +/- 73 seconds (0.3 ml) to 356 +/- 14 seconds (2.4 ml) in a dose-dependent manner. In TCCS, signal amplification appeared to be stronger with increasing doses. Adverse events were not observed during the study. This investigation describes the ultrasound enhancing potential of SonoVue in the intracranial cerebral circulation. SonoVue proved to be well tolerated and provided a long-lasting ultrasound contrast enhancement that supports an optimal transcranial ultrasound diagnostic.

Adult↗

PubMed1994

Leukocyte differentiation antigens in the bone marrow of patients with HIV-related disease.

To understand at what level hematopoiesis is impaired in AIDS patients, we quantitated bone marrow cells of the myeloid and lymphoid lineages in their different stages of differentiation. The bone marrow aspirates of 20 HIV-infected patients (18 with CDC IV) and 11 controls were analyzed by flow cytometry, using a panel of monoclonal antibodies. The mean percentages of CD34+ and CD10+ hematopoietic precursor cells were not significantly altered in the HIV-infected patients. The values of these patients however scattered in a much wider range than in the control group, some patients showing extremely high values. Patients with high levels of CD34+ and CD10+ precursor cells in the bone marrow had lower blood leukocyte counts and lower blood and bone marrow CD4 cell numbers than patients with a low percentage of CD10+ and CD34+ cells (p < 0.01). The percentages of the CD34+ cell subsets studied (CD34+CD33+, CD34+CD14+, CD34+CD15+) were not altered. Bone marrow CD4+ lymphocytes, especially those of CD45RA-phenotype, were reduced, while the CD8+ cells (especially HLA-DR+/CD45RA+ cells) were increased. These results show that the hematologic disorders in AIDS are not simply caused by an altered number or composition of bone marrow precursor cells. We postulate that hematopoiesis is inhibited due to an imbalance in the bone marrow T lymphocyte populations.

Acquired Immunodeficiency Syndrome↗